Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2023-03-20 Annual Report
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Samsung Pharm Co., Ltd. for the 69th fiscal year (2022). It contains comprehensive company information, business overview, capital structure, and detailed operational data. In the South Korean regulatory context, the 'Business Report' (사업보고서) is the equivalent of the US 10-K annual report, as it provides the full annual financial and operational disclosure required by the Financial Supervisory Service (FSS). FY 2022
2023-03-20 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고) for Samsung Pharmaceutical Co., Ltd. It includes the agenda for the upcoming annual general meeting, such as the approval of financial statements, election of directors, and amendments to the articles of incorporation. It also contains detailed financial statements (balance sheet, income statement) and management information. This type of document is standard for providing shareholders with the necessary information to vote at an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2023-03-08 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) and is a formal filing submitted to the Financial Supervisory Service (FSS) in South Korea. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including agenda items, proposed changes to the articles of incorporation, director nominations, and proxy voting procedures. This document is a standard proxy solicitation statement used to request shareholder votes for an upcoming meeting.
2023-03-08 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding a significant change (over 30%) in revenue or profit/loss structure. This is a standard Korean regulatory disclosure (DART system) used to inform the market of preliminary financial results before the final audit report is filed. Since it provides key financial highlights and explanations for the changes, it fits the definition of an Earnings Release (ER) as it serves as the initial announcement of financial performance for the period. FY 2022
2023-03-07 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samsung Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting details and to request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2023-03-07 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Samsung Pharmaceutical Co., Ltd. It contains the agenda for the upcoming Annual General Meeting (AGM), including financial statement approval, board appointments, and proposed amendments to the articles of incorporation. It also includes detailed proxy information, voting procedures, and financial summaries (balance sheets, income statements) intended for shareholder review prior to the meeting. This document is a standard proxy solicitation and information statement provided to shareholders to facilitate voting at the AGM.
2023-03-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.